<DOC>
	<DOCNO>NCT00000697</DOCNO>
	<brief_summary>To study safety effectiveness foscarnet treatment AIDS patient active infection cytomegalovirus ( CMV ) cause inflammation retina ( retinitis ) . In addition , patient treat ganciclovir ( DHPG ) toxic effect body 's blood-forming cell white blood cell platelet count low . CMV common virus , cause blindness death AIDS patient . Previous study demonstrate foscarnet effective AIDS non-AIDS patient CMV infection . Although treatment ganciclovir ( DHPG ) also effective , significant toxicity lead dose-limiting neutropenia ( low white blood cell count ) one third treat patient associated drug . Based serious nature CMV retinitis lack alternative drug therapy DHPG-sensitive patient , present study evaluate safety efficacy intravenous ( IV ) foscarnet AIDS patient CMV retinitis .</brief_summary>
	<brief_title>A Study Foscarnet Treatment Cytomegalovirus ( CMV ) Eyes Patients With AIDS Who Can Use Ganciclovir</brief_title>
	<detailed_description>CMV common virus , cause blindness death AIDS patient . Previous study demonstrate foscarnet effective AIDS non-AIDS patient CMV infection . Although treatment ganciclovir ( DHPG ) also effective , significant toxicity lead dose-limiting neutropenia ( low white blood cell count ) one third treat patient associated drug . Based serious nature CMV retinitis lack alternative drug therapy DHPG-sensitive patient , present study evaluate safety efficacy intravenous ( IV ) foscarnet AIDS patient CMV retinitis . Following routine evaluation study , patient randomize receive foscarnet right away delay treatment , retinitis determine immediately sight-threatening . Patients hospitalize first 3 day may remain hospitalize many 14 day . Foscarnet give vein ( IV ) call induction therapy , patient 's retinitis stabilize 2 week treatment , treatment foscarnet continue maintenance therapy another 8 week . During maintenance therapy , patient receive salt solution IV help prevent toxic side effect foscarnet kidney . Patients regular checkup monitor retinitis well general health . Patients take zidovudine ( AZT ) prior enter study may continue treatment select delayed treatment group ; select immediate treatment group , begin resume AZT therapy enter 2nd week maintenance therapy . Patients follow outpatient least 10 week , clinic check-ups lab test every week ; eye exams do week first 2 week every week . If clinically indicate , continue maintenance regimen may administer 10th week ; total duration therapy plus maintenance exceed 24 week . Note : Patients schedule delayed foscarnet treatment immediately give foscarnet first sign retinitis get bad .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed hematologically stable regimen least 30 day prior study entry : Oral antibiotic . Chemotherapy Kaposi 's sarcoma . Acyclovir outbreaks herpes simplex shingle . Zidovudine ( AZT ) , either initiated continue , patient randomize treatment arm . AZT give concurrently foscarnet may administer dose 100 200 mg every 4 hour ( q4h ) investigator 's discretion . Patients randomize delayed treatment arm may initiate continue AZT administration dose 100 200 mg q4h investigator 's discretion . AZT may administer first 3 week foscarnet therapy . Patients randomized immediate therapy may begin resume AZT enter 2nd week maintenance therapy ( week 4 10week study period ) , hemoglobin = &gt; 8 g/dl absolute neutrophil count = &gt; 1000 cells/mm3 time . Caution use concurrent use foscarnet ciprofloxacin , use appear exacerbate renal failure one patient . Patients must active AIDSrelated cytomegalovirus ( CMV ) retinitis identify characteristic ophthalmoscopic appearance verify fundus photography . Patients must also demonstrate one follow clinical and/or laboratory finding : Treatment ganciclovir ( DHPG ) result doselimiting toxicity ( absolute neutrophil count ( = polymorphonuclear leukocytes plus band ) &lt; 500 cells/mm3 platelet &lt; 25000 platelets/mm3 ) occur = &gt; two documented occasion least 7 day apart receive maximum induction regimen 10 mg/kg/day maintenance regimen 5 mg/kg/day . Neutropenia result zidovudine ( AZT ) treatment . Ineligibility DHPG therapy baseline neutropenia ( absolute neutrophil count &lt; 500 cells/mm3 ) thrombocytopenia ( platelet &lt; 25000 platelets/mm3 ) document = &gt; 2 occasion least 7 day apart . Baseline myelosuppression result ongoing therapy either prescription drug , include AZT , overthecounter medication . Prior Medication : Allowed : Zidovudine ( AZT ) , accord protocol stipulation . Prophylaxis therapy Pneumocystis carinii pneumonia ( PCP ) . Chemotherapy Kaposi 's sarcoma . Exclusion Criteria Coexisting Condition : Patients follow disease symptom exclude : An immediately sightthreatening lesion salvageable eye ( i.e. , patient cytomegalovirus ( CMV ) lesion within 1500 micron optic disc fovea eye correction vision 20/100 good ) . Corneal , lens vitreous opacification precludes examination fundus either eye . Any clinically significant pulmonary neurologic impairment ( i.e. , patient intubate comatose ) , although patient history seizure disorder central nervous system ( CNS ) mass lesion may enrol . Concurrent Medication : Excluded : Systemic acyclovir preventive therapy herpes infection . Any nephrotoxic agent . Specifically exclude aminoglycosides , amphotericin B , parenteral pentamidine . A patient require therapy must temporarily discontinue study therapy ; nephrotoxic therapy give &gt; 7 day , patient permanently withdraw study therapy . Other anticytomegalovirus ( CMV ) therapy , specifically ganciclovir , CMV hyperimmune serum/globulin , interferon , immunomodulators . Patients exclude study unwilling unable suspend zidovudine ( AZT ) treatment first 3 week study period ( 1 ) randomize immediate treatment arm , ( 2 ) crossedover delay treatment arm foscarnet therapy retinitis progression . Prior Medication : Excluded : Foscarnet cytomegalovirus ( CMV ) retinitis . Excluded within 7 day study entry : Immunomodulators . Investigational agent ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>